# PANDORA (NCT04995016)

> Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus axitinib
- Indication: locally advanced non-metastatic clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04995016
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Tianjin Medical University Second Hospital
- Conditions: Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma
- Interventions: Pembrolizumab; Axitinib
- Enrollment: 18
- Primary outcome: Major Pathologic Response (MPR)

## Indexed commentary on PANDORA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pandora-nct04995016